Verity Asset Management, Inc. Halozyme Therapeutics, Inc. Transaction History

Verity Asset Management, Inc.

$266 Billion
Q3 2024

A detailed history of Verity Asset Management, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Verity Asset Management, Inc. holds 38,248 shares of HALO stock, worth $1.83 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares

38,248

Previous 40,593 5.78%

Holding current value

$1.83 Million

Previous $2.13 Billion 3.0%

% of portfolio

0.82%

Previous 0.83%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$51.3 - $64.42 $120,298 - $151,064	-2,345 Reduced 5.78%	38,248 $2.19 Billion
Q2 2024 Aug 08, 2024	BUY	$37.81 - $52.4 $56,866 - $78,809	1,504 Added 3.85%	40,593 $2.13 Billion
Q1 2024 May 28, 2024	BUY	$33.68 - $41.95 $352,326 - $438,838	10,461 Added 36.54%	39,089 $1.59 Billion
Q4 2023 Feb 08, 2024	SELL	$33.32 - $42.1 $89,364 - $112,912	-2,682 Reduced 8.57%	28,628 $1.06 Billion
Q3 2023 Nov 22, 2023	BUY	$36.46 - $44.03 $209,316 - $252,776	5,741 Added 22.45%	31,310 $1.2 Billion
Q2 2023 Aug 15, 2023	SELL	$30.28 - $38.74 $175,139 - $224,072	-5,784 Reduced 18.45%	25,569 $922 Million
Q1 2023 May 24, 2023	BUY	$32.86 - $55.7 $157,005 - $266,134	4,778 Added 17.98%	31,353 $1.2 Billion
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $212,838 - $315,804	-5,313 Reduced 16.66%	26,575 $1.51 Billion
Q3 2022 Nov 15, 2022	BUY	$38.53 - $51.78 $22,809 - $30,653	592 Added 1.89%	31,888 $1.26 Billion
Q1 2022 May 12, 2022	SELL	$31.97 - $41.06 $143,896 - $184,811	-4,501 Reduced 12.57%	31,296 $1.25 Million
Q4 2021 Feb 08, 2022	BUY	$31.82 - $40.75 $176,791 - $226,407	5,556 Added 18.37%	35,797 $1.44 Million
Q3 2021 Nov 10, 2021	BUY	$38.47 - $46.42 $311,837 - $376,280	8,106 Added 36.62%	30,241 $1.23 Million
Q2 2021 Aug 04, 2021	BUY	$38.84 - $51.31 $109,723 - $144,950	2,825 Added 14.63%	22,135 $1.01 Million
Q1 2021 May 10, 2021	BUY	$39.51 - $51.45 $29,039 - $37,815	735 Added 3.96%	19,310 $805,000
Q4 2020 Feb 05, 2021	SELL	$25.81 - $43.62 $30,146 - $50,948	-1,168 Reduced 5.92%	18,575 $793,000
Q3 2020 Nov 13, 2020	SELL	$25.74 - $29.63 $60,823 - $70,015	-2,363 Reduced 10.69%	19,743 $519,000
Q2 2020 Nov 13, 2020	SELL	$16.25 - $26.81 $28,372 - $46,810	-1,746 Reduced 7.32%	22,106 $593,000
Q1 2020 May 18, 2020	SELL	$13.9 - $21.83 $81,801 - $128,469	-5,885 Reduced 19.79%	23,852 $429,000
Q4 2019 Feb 11, 2020	SELL	$14.93 - $19.53 $16,930 - $22,147	-1,134 Reduced 3.67%	29,737 $527,000
Q3 2019 Nov 01, 2019	SELL	$15.2 - $17.69 $6,961 - $8,102	-458 Reduced 1.46%	30,871 $479,000
Q2 2019 Aug 08, 2019	BUY	$14.75 - $17.26 $462,102 - $540,738	31,329 New	31,329 $538,000
Q2 2019 Aug 06, 2019	SELL	$14.75 - $17.26 $318,142 - $372,280	-21,569 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$13.94 - $17.58 $17,508 - $22,080	1,256 Added 6.18%	21,569 $347,000
Q4 2018 Feb 12, 2019	BUY	$13.33 - $18.66 $270,772 - $379,040	20,313 New	20,313 $297,000

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.66B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Verity Asset Management, Inc. with notifications on news.

Account

Verity Asset Management, Inc. Halozyme Therapeutics, Inc. Transaction History